Clinical Trial

A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to evaluate the long-term safety, tolerability, and efficacy of TLL-018 in patients with rheumatoid arthritis (RA) who have completed a preceding randomized controlled trial with TLL-018.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-14; most recent amendment 2026-05-18.
Trial Details
NCT Number NCT06887127
Lead Sponsor Hangzhou Highlightll Pharmaceutical Co., Ltd
Conditions Rheumatoid Arthritis
Enrollment 350 participants
Start Date 2025-03-10
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-20